REFERENCES
1. Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. Int J Med Sci 2012;9:193-9.
2. Pucci C, Martinelli C, Ciofani G. Innovative approaches for cancer treatment: current perspectives and new challenges. Ecancermedicalscience 2019;13:961.
3. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003;10:66-75.
4. Staniek J, Lorenzetti R, Heller B, et al. TRAIL-R1 and TRAIL-R2 mediate TRAIL-dependent apoptosis in activated primary human B lymphocytes. Front Immunol 2019;10:951.
5. Ndebele K, Gona P, Jin TG, et al. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induced mitochondrial pathway to apoptosis and caspase activation is potentiated by phospholipid scramblase-3. Apoptosis 2008;13:845-56.
6. Pistritto G, Trisciuoglio D, Ceci C, Garufi A, D'Orazi G. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY) 2016;8:603-19.
7. Kiraz Y, Adan A, Kartal Yandim M, Baran Y. Major apoptotic mechanisms and genes involved in apoptosis. Tumour Biol 2016;37:8471-86.
8. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003;22:8628-33.
9. Kalkavan H, Green DR. MOMP, cell suicide as a BCL-2 family business. Cell Death Differ 2018;25:46-55.
10. Refaat A, Abd-Rabou A, Reda A. TRAIL combinations: The new ‘trail’ for cancer therapy (Review). Oncol Lett 2014;7:1327-32.
11. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
12. Hymowitz SG, Christinger HW, Fuh G, et al. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 1999;4:563-71.
13. Micheau O. Regulation of TNF-related apoptosis-inducing ligand signaling by glycosylation. Int J Mol Sci 2018;19:715.
14. Naval J, de Miguel D, Gallego-Lleyda A, Anel A, Martinez-Lostao L. Importance of TRAIL molecular anatomy in receptor oligomerization and signaling. Implications for cancer therapy. Cancers 2019;11:444.
15. Lemke J, von Karstedt S, Zinngrebe J, Walczak H. Getting TRAIL back on track for cancer therapy. Cell Death Differ 2014;21:1350-64.
16. Trivedi R, Mishra DP. Trailing TRAIL resistance: novel targets for TRAIL sensitization in cancer cells. Front Oncol 2015;5:69.
17. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 2007;39:1462-75.
18. Ralff MD, El-Deiry WS. TRAIL pathway targeting therapeutics. Expert Rev Precis Med Drug Dev 2018;3:197-204.
19. Li H, Zhu H, Xu C, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998;94:491-501.
20. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998;94:481-90.
21. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome C-dependent caspase activation by eliminating IAP inhibition. Cell 2000;102:33-42.
22. Loreto C, La Rocca G, Anzalone R, et al. The role of intrinsic pathway in apoptosis activation and progression in Peyronie’s disease. Biomed Res Int 2014;2014:616149.
23. Snajdauf M, Havlova K, Vachtenheim J Jr, et al. The TRAIL in the treatment of human cancer: an update on clinical trials. Front Mol Biosci 2021;8:628332.
24. Wang K, Kievit FM, Jeon M, Silber JR, Ellenbogen RG, Zhang M. Nanoparticle-mediated target delivery of trail as gene therapy for glioblastoma. Adv Healthc Mater 2015;4:2719-26.
25. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005;12:228-37.
26. Yin N, Yi L, Khalid S, Ozbey U, Sabitaliyevich UY, Farooqi AA. TRAIL mediated signaling in breast cancer: awakening guardian angel to induce apoptosis and overcome drug resistance. In: Ahmad A, editor. Breast cancer metastasis and drug resistance. Cham: Springer International Publishing; 2019. pp. 243-52.
27. Dine JL, Garimella SV, Gehlhaus K, et al. Abstract 15: gp78 is a negative regulator of TRAIL-induced apoptosis in breast cancer cells. Cancer Res 2015;75:15-15.
29. Dianat-Moghadam H, Heidarifard M, Mahari A, et al. TRAIL in oncology: from recombinant TRAIL to nano- and self-targeted TRAIL-based therapies. Pharmacol Res 2020;155:104716.
30. Singh D, Tewari M, Singh S, Narayan G. Revisiting the role of TRAIL/TRAIL-R in cancer biology and therapy. Future Oncol 2021;17:581-96.
31. Zhang Y, Zhang B. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res 2008;6:1861-71.
32. Artykov AA, Yagolovich AV, Dolgikh DA, Kirpichnikov MP, Trushina DB, Gasparian ME. Death receptors DR4 and DR5 Undergo spontaneous and ligand-mediated endocytosis and recycling regardless of the sensitivity of cancer cells to TRAIL. Front Cell Dev Biol 2021;9:733688.
33. Shin MS, Kim HS, Lee SH, et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res 2001;61:4942-6.
34. Mérino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 2006;26:7046-55.
35. Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer 2005;5:54.
36. Wagner KW, Punnoose EA, Januario T, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007;13:1070-7.
37. Dufour F, Rattier T, Shirley S, et al. N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death. Cell Death Differ 2017;24:500-10.
38. Yeh WC, de la Pompa JL, McCurrach ME, et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 1998;279:1954-8.
39. Kuang AA, Diehl GE, Zhang J, Winoto A. FADD is required for DR4- and DR5-mediated apoptosis: lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts. J Biol Chem 2000;275:25065-8.
40. Zang F, Wei X, Leng X, Yu M, Sun B. C-FLIP(L) contributes to TRAIL resistance in HER2-positive breast cancer. Biochem Biophys Res Commun 2014;450:267-73.
41. Murtaza I, Saleem M, Adhami VM, Hafeez BB, Mukhtar H. Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells. Cancer Res 2009;69:1156-65.
42. Hassanzadeh A, Farshdousti Hagh M, Alivand MR, et al. Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL. J Cell Physiol 2018;233:6470-85.
43. Woo SM, Min KJ, Seo SU, et al. Axl inhibitor R428 enhances TRAIL-mediated apoptosis through downregulation of c-FLIP and survivin expression in renal carcinoma. Int J Mol Sci 2019;20:3253.
44. Geserick P, Drewniok C, Hupe M, et al. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. Oncogene 2008;27:3211-20.
45. Padmanabhan C, Rellinger EJ, Zhu J, et al. cFLIP critically modulates apoptotic resistance in epithelial-to-mesenchymal transition. Oncotarget 2017;8:101072-86.
46. Zhang L, Zhu H, Teraishi F, et al. Accelerated degradation of caspase-8 protein correlates with TRAIL resistance in a DLD1 human colon cancer cell line. Neoplasia 2005;7:594-602.
47. Robert E, McDonald Mc, El-Deiry WS. Suppression of caspase-8- and -10-associated RING proteins results in sensitization to death ligands and inhibition of tumor cell growth. Proceedings of the National Academy of Science;2004 101 (16) 6170-6175
48. Gillissen B, Wendt J, Richter A, et al. Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma. J Cell Biol 2010;188:851-62.
49. Kandasamy K, Srinivasula SM, Alnemri ES, et al. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. Cancer Res 2003;63:1712-21.
50. Sarosiek KA, Chi X, Bachman JA, et al. BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. Mol Cell 2013;51:751-65.
51. Han J, Goldstein LA, Gastman BR, et al. Differential involvement of Bax and Bak in TRAIL-mediated apoptosis of leukemic T cells. Leukemia 2004;18:1671-80.
52. Peña-Blanco A, García-Sáez AJ. Bax, Bak and beyond - mitochondrial performance in apoptosis. FEBS J 2018;285:416-31.
53. Hilmi C, Larribere L, Giuliano S, et al. IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin. J Invest Dermatol 2008;128:1499-505.
54. Adem J, Eray M, Eeva J, Nuutinen U, Pelkonen J. The combination of TRAIL and MG-132 induces apoptosis in both TRAIL-sensitive and TRAIL-resistant human follicular lymphoma cells. Leuk Res 2018;66:57-65.
55. Lamothe B, Aggarwal BB. Ectopic expression of Bcl-2 and Bcl-xL inhibits apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) through suppression of caspases-8, 7, and 3 and BID cleavage in human acute myelogenous leukemia cell line HL-60. J Interferon Cytokine Res 2002;22:269-79.
56. Fulda S, Meyer E, Debatin KM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002;21:2283-94.
57. Danish L, Imig D, Allgöwer F, Scheurich P, Pollak N. Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps. PLoS One 2018;13:e0198203.
58. Opel D, Naumann I, Schneider M, Bertele D, Debatin KM, Fulda S. Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma. Clin Cancer Res 2011;17:3233-47.
59. Garimella SV, Gehlhaus K, Dine JL, et al. Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening. Breast Cancer Res 2014;16:R41.
60. Werner TA, Nolten I, Dizdar L, et al. IAPs cause resistance to TRAIL-dependent apoptosis in follicular thyroid cancer. Endocr Relat Cancer 2018;25:295-308.
61. Pieczykolan JS, Kubiński K, Masłyk M, et al. AD-O53.2--a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L. Invest New Drugs 2014;32:1155-66.
62. Zhang S, Li G, Zhao Y, et al. Smac mimetic SM-164 potentiates APO2L/TRAIL- and doxorubicin-mediated anticancer activity in human hepatocellular carcinoma cells. PLoS One 2012;7:e51461.
63. Saraei R, Soleimani M, Movassaghpour Akbari AA, Farshdousti Hagh M, Hassanzadeh A, Solali S. The role of XIAP in resistance to TNF-related apoptosis-inducing ligand (TRAIL) in Leukemia. Biomed Pharmacother 2018;107:1010-9.
64. Jia L, Patwari Y, Kelsey SM, et al. Role of Smac in human leukaemic cell apoptosis and proliferation. Oncogene 2003;22:1589-99.
65. Metwalli AR, Khanbolooki S, Jinesh G, et al. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Cancer Biol Ther 2010;10:885-92.
66. Wu MS, Wang GF, Zhao ZQ, et al. Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma. Mol Cancer Ther 2013;12:1728-37.
67. Dai Y, Liu M, Tang W, et al. A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB. BMC Cancer 2009;9:392.
68. Zhang XD, Zhang XY, Gray CP, Nguyen T, Hersey P. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res 2001;61:7339-48.
69. Li P, Li S, Yin D, et al. EGCG sensitizes human nasopharyngeal carcinoma cells to TRAIL-mediated apoptosis by activation NF-κB. Neo 2017;64:74-80.
70. Rasheduzzaman M, Jeong JK, Park SY. Resveratrol sensitizes lung cancer cell to TRAIL by p53 independent and suppression of Akt/NF-κB signaling. Life Sci 2018;208:208-20.
71. Liu PC, Lu G, Deng Y, et al. Inhibition of NF-κB pathway and modulation of MAPK signaling pathways in glioblastoma and implications for lovastatin and tumor necrosis factor-related apoptosis inducing ligand (TRAIL) combination therapy. PLoS One 2017;12:e0171157.
72. Geismann C, Grohmann F, Sebens S, et al. c-Rel is a critical mediator of NF-κB-dependent TRAIL resistance of pancreatic cancer cells. Cell Death Dis 2014;5:e1455.
73. Li SS, Tang QL, Wang SH, Wang S, Yang XM. Simultaneously targeting bcl-2 and Akt pathways sensitizes nasopharyngeal carcinoma to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Biother Radiopharm 2012;27:88-95.
74. Xu J, Zhou JY, Wei WZ, Wu GS. Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. PLoS One 2010;5:e10226.
75. Dida F, Li Y, Iwao A, Deguchi T, Azuma E, Komada Y. Resistance to TRAIL-induced apoptosis caused by constitutional phosphorylation of Akt and PTEN in acute lymphoblastic leukemia cells. Exp Hematol 2008;36:1343-53.
76. Plastaras JP, Dorsey JF, Carroll K, Kim SH, Birnbaum MJ, El-Deiry WS. Role of PI3K/Akt signaling in TRAIL- and radiation-induced gastrointestinal apoptosis. Cancer Biol Ther 2008;7:2047-53.
77. Goncharenko-Khaider N, Lane D, Matte I, Rancourt C, Piché A. The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells. Oncogene 2010;29:5523-36.
78. Cao L, Du P, Jiang SH, Jin GH, Huang QL, Hua ZC. Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature. Mol Cancer Ther 2008;7:851-61.
79. Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 2009;4:34-41.
80. ClinicalTrials.gov. A study of AMG 951 [rhApo2L/TRAIL] in subjects with previously untreated non-small cell lung cancer (NSCLC) treated with chemotherapy +/- bevacizumab. Available from: https://clinicaltrials.gov/ct2/show/NCT00508625 [Last accessed on 30 Jan 2023].
81. ClinicalTrials.gov. A study of dulanermin administered in combination with the FOLFOX regimen and bevacizumab in patients with previously untreated, locally advanced, recurrent, or metastatic colorectal cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT00873756 [Last accessed on 30 Jan 2023].
82. ClinicalTrials.gov. A phase III trial of recombinant human Apo-2 ligand for injection. Available from: https://clinicaltrials.gov/ct2/show/NCT03083743 [Last accessed on 30 Jan 2023].
83. ClinicalTrials.gov. Study of Mapatumumab in combination with bortezomib (Velcade) and bortezomib alone in subjects with relapsed or refractory multiple myeloma. Available from: https://clinicaltrials.gov/ct2/show/NCT00315757 [Last accessed on 30 Jan 2023].
84. ClinicalTrials.gov. Study of mapatumumab in combination with Sorafenib in subjects with advanced hepatocellular carcinoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01258608 [Last accessed on 30 Jan 2023].
85. ClinicalTrials.gov. A study of mapatumumab in combination with paclitaxel and carboplatin in subjects with non-small cell lung cancer (NSCLC). Available from: https://clinicaltrials.gov/ct2/show/NCT00583830 [Last accessed on 30 Jan 2023].
86. ClinicalTrials.gov. Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects with relapsed or refractory Non-Hodgkin’s lymphoma (NHL). Available from: https://clinicaltrials.gov/ct2/show/NCT00094848 [Last accessed on 30 Jan 2023].
87. ClinicalTrials.gov. CS-1008 with carboplatin/paclitaxel in chemotherapy naïve subjects with metastatic or unresectable non-small cell lung cancer (NSCLC). Available from: https://clinicaltrials.gov/ct2/show/NCT00991796 [Last accessed on 30 Jan 2023].
88. ClinicalTrials.gov. Open-label study of CS-1008 for subjects with untreated and unresectable pancreatic cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT00521404 [Last accessed on 30 Jan 2023].
89. ClinicalTrials.gov. Abraxane with or without tigatuzumab in patients with metastatic, triple negative breast cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01307891 [Last accessed on 30 Jan 2023].
90. ClinicalTrials.gov. CS1008- in combination with sorafenib compared to sorafenib alone in subjects with advanced liver cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01033240 [Last accessed on 30 Jan 2023].
91. ClinicalTrials.gov. Phase 1b lymphoma study of AMG 655 in combination with bortezomib or vorinostat. Available from: https://clinicaltrials.gov/ct2/show/NCT00791011 [Last accessed on 30 Jan 2023].
92. ClinicalTrials.gov. QUILT-2.019: A study of AMG 655 or AMG 479 in combination with gemcitabine for treatment of metastatic pancreatic cancer. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00630552 [Last accessed on 30 Jan 2023].
93. ClinicalTrials.gov. Phase 1b/2 study of AMG 655 with mFOLFOX6 and bevacizumab for first-line metastatic colorectal cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT00625651 [Last accessed on 30 Jan 2023].
94. Dubuisson A, Micheau O. Antibodies and derivatives targeting DR4 and DR5 for cancer therapy. Antibodies 2017;6:16.
95. Soria JC, Márk Z, Zatloukal P, et al. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol 2011;29:4442-51.
96. von Pawel J, Harvey JH, Spigel DR, et al. Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Clin Lung Cancer 2014;15:188-196.e2.
97. Cheng AL, Kang YK, He AR, et al. Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: a phase 2 randomized study. J Hepatol 2015;63:896-904.
98. Reck M, Krzakowski M, Chmielowska E, et al. A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer. Lung Cancer 2013;82:441-8.
99. Forero-Torres A, Holkova B, Goldschmidt J, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood 2015;126:2798-804.
100. Fuchs CS, Fakih M, Schwartzberg L, et al. TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: a randomized phase 1b/2 trial. Cancer 2013;119:4290-8.
101. Twomey JD, Kim SR, Zhao L, Bozza WP, Zhang B. Spatial dynamics of TRAIL death receptors in cancer cells. Drug Resist Updat 2015;19:13-21.
102. Yao Y, Zhou Y, Liu L, et al. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci 2020;7:193.
103. Mottaghitalab F, Farokhi M, Fatahi Y, Atyabi F, Dinarvand R. New insights into designing hybrid nanoparticles for lung cancer: diagnosis and treatment. J Control Release 2019;295:250-67.
104. Zakaria AB, Picaud F, Rattier T, et al. Nanovectorization of TRAIL with single wall carbon nanotubes enhances tumor cell killing. Nano Lett 2015;15:891-5.
105. Jiang T, Sun W, Zhu Q, et al. Furin-mediated sequential delivery of anticancer cytokine and small-molecule drug shuttled by graphene. Adv Mater 2015;27:1021-8.
106. Arroyo N, Herlem G, Picaud F. Ligand nanovectorization using graphene to target cellular death receptors of cancer cell. Proteins 2020;88:94-105.
107. Lotfollahzadeh S, Hosseini ES, Aznaveh MH, et al. TRAIL/S-layer/graphene quantum dot nanohybrid enhanced stability and anticancer activity of TRAIL on colon cancer cells. Sci Rep 2022;12:5851.
108. Huang YJ, Hsu SH. TRAIL-functionalized gold nanoparticles selectively trigger apoptosis in polarized macrophages. Nanotheranostics 2017;1:326-37.
109. Ke S, Zhou T, Yang P, et al. Gold nanoparticles enhance TRAIL sensitivity through Drp1-mediated apoptotic and autophagic mitochondrial fission in NSCLC cells. Int J Nanomedicine 2017;12:2531-51.
110. Birtekocak F, Demirbolat GM, Cevik O. TRAIL conjugated silver nanoparticle synthesis, characterization and therapeutic effects on HT-29 colon cancer cells. Iran J Pharm Res 2021;20:45-56.
111. Sur-Erdem I, Muslu K, Pınarbası N, et al. TRAIL-conjugated silver nanoparticles sensitize glioblastoma cells to TRAIL by regulating CHK1 in the DNA repair pathway. Neurol Res 2020;42:1061-9.
112. Gallego-Lleyda A, De Miguel D, Anel A, Martinez-Lostao L. Lipid nanoparticles decorated with TNF-related aptosis-inducing ligand (TRAIL) Are more cytotoxic than soluble recombinant TRAIL in sarcoma. Int J Mol Sci 2018;19:1449.
113. De Miguel D, Gallego-Lleyda A, Ayuso JM, et al. Improved anti-tumor activity of novel highly bioactive liposome-bound TRAIL in breast cancer cells. Recent Pat Anticancer Drug Discov 2016;11:197-214.
114. Miguel D, Gallego-Lleyda A, Anel A, Martinez-Lostao L. Liposome-bound TRAIL induces superior DR5 clustering and enhanced DISC recruitment in histiocytic lymphoma U937 cells. Leuk Res 2015;39:657-66.
115. De Miguel D, Gallego-lleyda A, Ayuso JM, et al. TRAIL-coated lipid-nanoparticles overcome resistance to soluble recombinant TRAIL in non-small cell lung cancer cells. Nanotechnology 2016;27:185101.
116. De Miguel D, Gallego-Lleyda A, Ayuso JM, et al. High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer. Cancer Lett 2016;383:250-60.
117. Li Q, Ding Y, Guo X, et al. Chemically modified liposomes carrying TRAIL target activated hepatic stellate cells and ameliorate hepatic fibrosis in vitro and
118. Jun H, Jang E, Kim H, et al. TRAIL & EGFR affibody dual-display on a protein nanoparticle synergistically suppresses tumor growth. J Control Release 2022;349:367-78.
119. Thao le Q, Byeon HJ, Lee C, et al. Doxorubicin-bound albumin nanoparticles containing a TRAIL protein for targeted treatment of colon cancer. Pharm Res 2016;33:615-26.
120. Shi Y, Wang J, Liu J, et al. Oxidative stress-driven DR5 upregulation restores TRAIL/Apo2L sensitivity induced by iron oxide nanoparticles in colorectal cancer. Biomaterials 2020;233:119753.
121. Perlstein B, Finniss SA, Miller C, et al. TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and
122. Belkahla H, Constantinescu AA, Gharbi T, et al. Grafting TRAIL through either amino or carboxylic groups onto maghemite nanoparticles: influence on pro-apoptotic efficiency. Nanomaterials 2021;11:502.
123. Wang MS, Chen L, Xiong YQ, Xu J, Wang JP, Meng ZL. Iron oxide magnetic nanoparticles combined with actein suppress non-small-cell lung cancer growth in a p53-dependent manner. Int J Nanomedicine 2017;12:7627-51.
124. Shakil MS, Hasan MA, Sarker SR. Iron Oxide Nanoparticles for breast cancer theranostics. Curr Drug Metab 2019;20:446-56.
125. Liu H, Zhang J, Chen X, et al. Application of iron oxide nanoparticles in glioma imaging and therapy: from bench to bedside. Nanoscale 2016;8:7808-26.
126. Huang K, Duan N, Zhang C, Mo R, Hua Z. Improved antitumor activity of TRAIL fusion protein via formation of self-assembling nanoparticle. Sci Rep 2017;7:41904.
127. Hadad E, Rudnick-Glick S, Itzhaki E, et al. Engineering of doxorubicin-encapsulating and TRAIL-conjugated poly(RGD) proteinoid nanocapsules for drug delivery applications. Polymers 2020;12:2996.
128. Zhang ZQ, Song SC. Multiple hyperthermia-mediated release of TRAIL/SPION nanocomplex from thermosensitive polymeric hydrogels for combination cancer therapy. Biomaterials 2017;132:16-27.
129. Riehle R, Pattni B, Jhaveri A, et al. Combination nanopreparations of a novel proapoptotic drug - NCL-240, TRAIL and siRNA. Pharm Res 2016;33:1587-601.
130. Wang S, Shao M, Zhong Z, et al. Co-delivery of gambogic acid and TRAIL plasmid by hyaluronic acid grafted PEI-PLGA nanoparticles for the treatment of triple negative breast cancer. Drug Deliv 2017;24:1791-800.
131. Jiang X, Fitch S, Wang C, et al. Nanoparticle engineered TRAIL-overexpressing adipose-derived stem cells target and eradicate glioblastoma via intracranial delivery. Proc Natl Acad Sci USA 2016;113:13857-62.
132. Lee AL, Dhillon SH, Wang Y, Pervaiz S, Fan W, Yang YY. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles. Mol Biosyst 2011;7:1512-22.
133. Skidan I, Miao B, Thekkedath RV, Dholakia P, Degterev A, Torchilin V. In vitro cytotoxicity of novel pro-apoptotic agent DM-PIT-1 in PEG-PE-based micelles alone and in combination with TRAIL. Drug Deliv 2009;16:45-51.
134. Lim SM, Kim TH, Jiang HH, et al. Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles. Biomaterials 2011;32:3538-46.
135. Yang X, Li Z, Wu Q, Chen S, Yi C, Gong C. TRAIL and curcumin codelivery nanoparticles enhance TRAIL-induced apoptosis through upregulation of death receptors. Drug Deliv 2017;24:1526-36.
136. Feng C, Han X, Chi L, Sun J, Gong F, Shen Y. Synthesis, characterization, and in vitro evaluation of TRAIL-modified, cabazitaxel -loaded polymeric micelles for achieving synergistic anticancer therapy. J Biomater Sci Polym Ed 2018;29:1729-44.
137. Zhong HH, Wang HY, Li J, Huang YZ. TRAIL-based gene delivery and therapeutic strategies. Acta Pharmacol Sin 2019;40:1373-85.
138. Wei W, Xu C, Wu H. Magnetic iron oxide nanoparticles mediated gene therapy for breast cancer - an in vitro study. J Huazhong Univ Sci Technolog Med Sci 2006;26:728-30.
139. Li F, Niu S, Sun J, Zhu H, Ba Q, Guo Y, Shi D. Efficient in vitro TRAIL-gene delivery in drug-resistant A2780/DDP ovarian cancer cell line via magnetofection. J Nanomater 2011;2011:1-7.
140. Alvizo-Baez CA, Luna-Cruz IE, Vilches-Cisneros N, Rodríguez-Padilla C, Alcocer-González JM. Systemic delivery and activation of the TRAIL gene in lungs, with magnetic nanoparticles of chitosan controlled by an external magnetic field. Int J Nanomedicine 2016;11:6449-58.
141. Miao L, Zhang K, Qiao C, et al. Antitumor effect of human TRAIL on adenoid cystic carcinoma using magnetic nanoparticle-mediated gene expression. Nanomedicine 2013;9:141-50.
142. Jiang J, Tan Y, Deng Q, et al. Gold nanoparticles conjugated to the secretable trimeric TRAIL gene promote apoptosis in heat-shocked hepatoma cells. Int J Clin Exp Med 2017;10:14047-55.
143. Sharkawi FZ, Ewais SM, Fahmy RH, Rashed LA. PTEN and TRAIL genes loaded zein nanoparticles as potential therapy for hepatocellular carcinoma. J Drug Target 2017;25:513-22.
144. Li N, Gao D, Li C, et al. Polymer Nanoparticles Overcome Drug Resistance by a Dual-Targeting Apoptotic Signaling Pathway in Breast Cancer. ACS Appl Mater Interf ;2022:23117-28.
145. Vaughan HJ, Zamboni CG, Radant NP, et al. Poly(beta-amino ester) nanoparticles enable tumor-specific TRAIL secretion and a bystander effect to treat liver cancer. Mol Ther Oncolytics 2021;21:377-88.
146. Miao L, Liu C, Ge J, et al. Antitumor effect of TRAIL on oral squamous cell carcinoma using magnetic nanoparticle-mediated gene expression. Cell Biochem Biophys 2014;69:663-72.
147. Pishavar E, Attaranzadeh A, Alibolandi M, Ramezani M, Hashemi M. Modified PAMAM vehicles for effective TRAIL gene delivery to colon adenocarcinoma: in vitro and
148. Zheng Y, Chen H, Zeng X, et al. Surface modification of TPGS-b-(PCL-ran-PGA) nanoparticles with polyethyleneimine as a co-delivery system of TRAIL and endostatin for cervical cancer gene therapy. Nanoscale Res Lett 2013;8:161.
149. Wang Y, Li L, Shao N, et al. Triazine-modified dendrimer for efficient TRAIL gene therapy in osteosarcoma. Acta Biomater 2015;17:115-24.
150. Li L, Song L, Yang X, et al. Multifunctional “core-shell” nanoparticles-based gene delivery for treatment of aggressive melanoma. Biomaterials 2016;111:124-37.
151. Tzeng SY, Wilson DR, Hansen SK, Quiñones-Hinojosa A, Green JJ. Polymeric nanoparticle-based delivery of TRAIL DNA for cancer-specific killing. Bioeng Transl Med 2016;1:149-59.
152. Li L, Li X, Wu Y, et al. Multifunctional nucleus-targeting nanoparticles with ultra-high gene transfection efficiency for
153. Song L, Liang X, Yang S, et al. Novel polyethyleneimine-R8-heparin nanogel for high-efficiency gene delivery in vitro and
154. Xu F, Zhong H, Chang Y, et al. Targeting death receptors for drug-resistant cancer therapy: codelivery of pTRAIL and monensin using dual-targeting and stimuli-responsive self-assembling nanocomposites. Biomaterials 2018;158:56-73.
155. Fan H, Hu QD, Xu FJ, Liang WQ, Tang GP, Yang WT.
156. Sun NF, Meng QY, Tian AL, et al. Nanoliposome-mediated FL/TRAIL double-gene therapy for colon cancer:
157. Liu CH, Chern GJ, Hsu FF, et al. A multifunctional nanocarrier for efficient TRAIL-based gene therapy against hepatocellular carcinoma with desmoplasia in mice. Hepatology 2018;67:899-913.
158. Luo C, Miao L, Zhao Y, et al. A novel cationic lipid with intrinsic antitumor activity to facilitate gene therapy of TRAIL DNA. Biomaterials 2016;102:239-48.
159. Chen K, Cao X, Li M, et al. A TRAIL-delivered lipoprotein-bioinspired nanovector engineering stem cell-based platform for inhibition of lung metastasis of melanoma. Theranostics 2019;9:2984-98.
